Altimmune (ALT) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free ALT Stock Alerts $7.82 +0.45 (+6.11%) (As of 05:26 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 3:37 PM | markets.businessinsider.comBuy Rating Justified: Altimmune’s Pemvidutide Shows Best-in-Class Potential for Obesity and MASHMay 14 at 1:38 PM | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)May 14 at 8:19 AM | marketbeat.comAltimmune (NASDAQ:ALT) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research note on Tuesday.May 14 at 5:45 AM | prnewswire.comContact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)May 14 at 4:00 AM | prnewswire.comALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 13 at 6:40 AM | prnewswire.comALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMay 12 at 4:34 AM | americanbankingnews.comJMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $24.00May 11 at 11:27 PM | markets.businessinsider.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 11 at 12:32 PM | finance.yahoo.comAltimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)May 11 at 2:07 AM | markets.businessinsider.comBuy Rating Affirmed for Altimmune on Pemvidutide’s Potential and Strategic AdvancementsMay 11 at 2:04 AM | americanbankingnews.comAltimmune (NASDAQ:ALT) Trading Down 4.7% After Analyst DowngradeMay 10, 2024 | businesswire.comAltimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class ActionMay 10, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Stock Price Down 4.7% on Analyst DowngradeAltimmune (NASDAQ:ALT) Shares Down 4.7% Following Analyst DowngradeMay 10, 2024 | finance.yahoo.comAltimmune Inc (ALT) Reports Q1 2024 Financials: A Detailed ReviewMay 10, 2024 | markets.businessinsider.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 10, 2024 | msn.comAltimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comJMP Securities Trims Altimmune (NASDAQ:ALT) Target Price to $24.00JMP Securities cut their price objective on shares of Altimmune from $25.00 to $24.00 and set a "market outperform" rating on the stock in a research note on Friday.May 10, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAltimmune (NASDAQ:ALT - Get Free Report) posted its earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.02. The business had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. During the same period in the previous year, the firm posted ($0.40) earnings per share.May 10, 2024 | uk.finance.yahoo.comQ1 2024 Altimmune Inc Earnings CallMay 10, 2024 | prnewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) ShareholdersMay 9, 2024 | stockhouse.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 9, 2024 | prnewswire.comINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law FirmMay 9, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Trading Up 8.1%Altimmune (NASDAQ:ALT) Shares Up 8.1%May 9, 2024 | msn.comALT Stock Earnings: Altimmune Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deAltimmune, Inc: Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | globenewswire.comAltimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 8, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 8, 2024 | markets.businessinsider.comAltimmune earnings: here's what Wall Street expectsMay 8, 2024 | tmcnet.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsMay 8, 2024 | stockhouse.comALTIMMUNE, INC. (NASDAQ:ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming DeadlineMay 8, 2024 | americanbankingnews.comAltimmune (ALT) Scheduled to Post Earnings on ThursdayMay 8, 2024 | msn.comClass Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLPMay 7, 2024 | prnewswire.comALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 7, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsMay 7, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsMay 7, 2024 | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALTMay 7, 2024 | cnbc.comAmgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominanceMay 7, 2024 | benzinga.comJim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'May 7, 2024 | globenewswire.comAltimmune to Participate at Two Upcoming Investor ConferencesMay 6, 2024 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Altimmune, Inc. and Certain Officers - ALTMay 6, 2024 | stockhouse.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 3, 2024 | msn.comAmgen stock rallies 13% on GLP-1 weight-loss drug updateMay 3, 2024 | marketbeat.comAltimmune (ALT) Set to Announce Earnings on ThursdayAltimmune (NASDAQ:ALT) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 2, 2024 | globenewswire.comAltimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024May 1, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 9.9%Altimmune (NASDAQ:ALT) Trading 9.9% HigherMay 1, 2024 | globenewswire.comAltimmune to Participate at Two Upcoming ConferencesApril 30, 2024 | markets.businessinsider.comBriumvi’s Market Share Growth and TG Therapeutics’ Strong Financial Outlook Justify Buy RatingApril 30, 2024 | benzinga.comPeering Into Altimmune's Recent Short InterestApril 29, 2024 | msn.comDeutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market SessionApril 29, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Downgraded by GuggenheimGuggenheim lowered Altimmune from a "buy" rating to a "neutral" rating in a research note on Monday. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address America could fall from this event (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash. Click here to see how you can protect yourself today. ALT Media Mentions By Week ALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.160.57▲Average Medical News Sentiment ALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼405▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KalVista Pharmaceuticals News Verve Therapeutics News Travere Therapeutics News Larimar Therapeutics News Oculis News Shattuck Labs News COMPASS Pathways News Adlai Nortye News Arbutus Biopharma News Astria Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
